Harmonisierung der Diagnostik und Therapie der systemischen juvenilen idiopathischen Arthritis in Deutschland

C. H. Hinze; D. Holzinger; E. Lainka; J.-P. Haas; F. Speth; T. Kallinich; N. Rieber; M. Hufnagel; A. F. Jansson; C. Hedrich; H. Winowski; G. Horneff; D. Föll

doi:10.1055/s-0037-1618435

Arthritis und Rheuma, Inhaltsverzeichnis

Arthritis und Rheuma 2017; 37(04): 250-259
DOI: 10.1055/s-0037-1618435

Kinderrheumatologie/GKJR-Kommission PRO-KIND: Protokolle

Schattauer GmbH

Harmonisierung der Diagnostik und Therapie der systemischen juvenilen idiopathischen Arthritis in Deutschland

Prozessbeschreibung und KernaussagenThe German PRO-KIND project group on SJIAstatus report 2017

C. H. Hinze

¹Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster

,

D. Holzinger

¹Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster

,

E. Lainka

²Klinik für Kinder-und Jugendmedizin, Universitätskinderklinik Essen, Essen

,

J.-P. Haas

³Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen

,

F. Speth

⁴Klinik für Kinder- und Jugendheilkunde, Universitätsmedizin Rostock, Rostock

,

T. Kallinich

⁵Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie, Charité Berlin, Berlin

,

N. Rieber

⁶Kinderklinik München Schwabing, Klinik und Poliklinik für Kinder- und Jugendmedizin, Klinikum Schwabing, StKM GmbH und Klinikum rechts der Isar (AöR), Technische Universität München, München

,

M. Hufnagel

⁷Klinik für Allgemeine Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Freiburg

,

A. F. Jansson

⁸Abteilung für Rheumatologie & Immunologie, Dr. von Haunersches Kinderspital, Klinikum der Universität München, München

,

C. Hedrich

⁹Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden

,

H. Winowski

¹⁰Klinik für Kinder- und Jugendrheumatologie, St. Josef-Stift Sendenhorst, Sendenhorst

,

G. Horneff

¹¹Allgemeine Kinder- und Jugendmedizin, Kinderklinik Sankt Augustin, Asklepios Klinik Sankt Augustin, Sankt Augustin

,

D. Föll

¹Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster

¹²für die PRO-KIND SJIA-Projektgruppe

Literatur
1 Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nature reviews Rheumatology 2011; 7 (07) 416-426.
2 Calabro JJ, Marchesano JM. Fever associated with juvenile rheumatoid arthritis. The New England journal of medicine 1967; 276 (01) 11-18.
3 Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the rheumatic diseases 2012; 71 (09) 1437-1439.
4 Behrens EM, Beukelman T, Gallo L. et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). The Journal of rheumatology 2008; 35 (02) 343-348.
5 Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S. et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still‘s disease. The Journal of rheumatology 2001; 28 (02) 322-329.
6 Yamaguchi M, Ohta A, Tsunematsu T. et al. Preliminary criteria for classification of adult Still‘s disease. The Journal of rheumatology 1992; 19 (03) 424-430.
7 Ansell BM. Problems of corticosteroid therapy in the young. Proceedings of the Royal Society of Medicine 1968; 61 (03) 281-282.
8 Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C. 6-methylprednisolone ‚mini-pulses‘: a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scandinavian journal of rheumatology 1996; 25 (01) 24-27.
9 De Benedetti F, Brunner HI, Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 2012; 367 (25) 2385-2395.
10 Quartier P, Allantaz F, Cimaz R. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Annals of the rheumatic diseases 2011; 70 (05) 747-754.
11 Ruperto N, Brunner HI, Quartier P. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 2012; 367 (25) 2396-2406.
12 Beukelman T, Patkar NM, Saag KG. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care & research 2011; 63 (04) 465-482.
13 DeWitt EM, Kimura Y, Beukelman T. et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis care & research 2012; 64 (07) 1001-1010.
14 Ringold S, Weiss PF, Beukelman T. et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis and rheumatism 2013; 65 (10) 2499-2512.
15 Vastert SJ, de Jager W, Noordman BJ. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis & rheumatology (Hoboken, NJ) 2014; 66 (04) 1034-1043.
16 Dueckers G, Guellac N, Arbogast M. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical immunology (Orlando, Fla) 2012; 142 (02) 176-193.
17 Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis & rheumatology (Hoboken, NJ) 2014; 66 (06) 1405-1413.
18 Group OLo EW. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) 2009. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levelsevidence-march-2009/
19 Koolman AH, Kamphuis SS, Weggelaar NM. et al. [Children with fever peaks and bone and joint pain: systemic juvenile idiopathic arthritis or acute lymphoblastic leukemia after all?]. Nederlands tijdschrift voor geneeskunde 2002; 146 (35) 1613-1616.
20 Suri D, Ahluwalia J, Sachdeva MU. et al. Arthritic presentation of childhood malignancy: beware of normal blood counts. Rheumatology international 2011; 31 (06) 827-829.
21 Tamashiro MS, Aikawa NE, Campos LM. et al. Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset. Clinics (Sao Paulo, Brazil) 2011; 66 (10) 1665-1669.
22 Trapani S, Grisolia F, Simonini G. et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Seminars in arthritis and rheumatism 2000; 29 (06) 348-359.
23 Kallinich T, Lainka E, Berner R, Niehues T. Leitlinie der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Kinder- und Jugendmedizin: Fieber unklarer Genese 2013 [cited 2016]. Available from: http://www.awmf.org/leitlinien/detail/ll/027-053.html
24 Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?. Rheumatology (Oxford, England) 2005; 44 (11) 1350-1353.
25 Ombrello MJ, Remmers EF, Tachmazidou I. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America 2015; 112 (52) 15970-15975.
26 Put K, Vandenhaute J, Avau A. et al. Inflammatory gene expression profile and defective IFN-gamma and granzyme K in natural killer cells of systemic juvenile idiopathic arthritis patients. Arthritis & rheumatology (Hoboken, NJ) 2016
27 Gohar F, Kessel C, Lavric M. et al. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?. Arthritis research & therapy 2016; 18: 163
28 Holzinger D, Frosch M, Kastrup A. et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Annals of the rheumatic diseases 2012; 71 (06) 974-980.
29 Wittkowski H, Frosch M, Wulffraat N. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis and rheumatism 2008; 58 (12) 3924-3931.
30 Nigrovic PA, Mannion M, Prince FH. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis and rheumatism 2011; 63 (02) 545-555.
31 Ruperto N, Quartier P, Wulffraat N. et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and rheumatism 2012; 64 (02) 557-567.
32 Passo MH, Taylor J. Quality improvement in pediatric rheumatology: what do we need to do?. Current opinion in rheumatology 2008; 20 (05) 625-630.